Last reviewed · How we verify

NCT07264114

Aquatic High-Intensity Interval Training for Parkinson's Disease

Active, enrolled NA Last updated 18 February 2026
What this trial tests

NA trial testing Aquatic HIIT with adherence/support package in Parkinson Disease in 56 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
10 December 2025
Primary endpoint
10 March 2026
10 June 2026

Quick facts

Lead sponsorPardis Specialized Wellness Institute
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment56
Start date10 December 2025
Primary completion10 March 2026
Estimated completion10 June 2026
Sites1 location across Iran

Drugs / interventions tested

Conditions studied

Sponsor

Pardis Specialized Wellness Institute

Who can join

Adults 55 to 75, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, single-center, parallel-group superiority trial will evaluate the effect of an 8-week aquatic High-Intensity Interval Training (HIIT) program on balance, physical function, and sarcopenia-related outcomes in individuals with Parkinson's disease (PD). The intervention aims to deliver Tabata-style aquatic HIIT (3 sessions/week) in a therapeutic pool to determine adherence and preliminary efficacy compared with standard care (no structured exercise program).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other Pardis Specialized Wellness Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07264114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing